Emmes Launches Orphan Reach


Emmes, a full service, global clinical research organization(CRO), is launching its new center, Orphan Reach as a ‘rare CRO’.

The new rare disease center will incorporate Emmes’ reputation in public health research across the public sector and biopharmaceutical industry, with the knowledge of Orphan Reach, a UK-based specialty CRO acquired by Emmes in May 2021. The addition of Emmes’ biostatistics, data management, and global clinical trial execution capabilities will enable the center to function as a full, end to end services organization.

The expanded Orphan Reach forms a global specialty center dedicated to the advancement of rare disease research by providing specialized clinical trial design and execution capabilities.

Emmes Launches Orphan Reach

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.